TherapeuticsMD Expands Commercial and Business Development Leadership

Dawn Halkuff appointed Chief Commercial Officer –

– Yulii Bogatyrenko appointed Senior Vice President of Business
Development –

BOCA RATON, Fla.–(BUSINESS WIRE)–TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare
company, today announced two new strategic hires: Dawn Halkuff as Chief
Commercial Officer and Yulii Bogatyrenko as Senior Vice President of
Business Development. Both executives bring women’s health experience
and relevant skills to the company in advance of the potential launch of
its first bio-identical hormone therapy drug candidate in the second
half of 2017.

“We are extremely pleased that Dawn and Yulii are joining our executive
team, bringing key commercial and business development capabilities to
our company, and strengthening our overall women’s health expertise,”
said TherapeuticsMD CEO Robert G. Finizio. “Dawn is a proven women’s
health expert with commercial, sales and marketing experience specific
to post-menopausal women, and she has a sophisticated understanding of
how to motivate women and healthcare professionals. Yulii has tremendous
long-term relationships both internationally and domestically in the
pharmaceutical industry. We believe that these two seasoned
professionals will help us successfully launch our advanced hormone
therapy products, if approved.”

Dawn Halkuff has held numerous senior level positions over 20 years of
commercial and marketing experience. She was previously at Pfizer, Inc.
(NYSE: PFE), where she held various leadership roles in women’s health
since 2010. Most recently, she was Senior Vice President of the Pfizer
Consumer Healthcare Wellness Organization and a member of the Consumer
Global Leadership Team. Prior to that, Ms. Halkuff was commercial lead
for sales and marketing of the Pfizer Women’s Health Division, focusing
on the company’s reinvestment in hormone therapy treatment, including
Premarin Vaginal Cream® and oral hot flash treatments. From
2005 to 2010, Ms. Halkuff was Head of Global Innovation at Weight
Watchers International (NYSE: WTW), where she created new weight-loss
products, services, and solutions for women worldwide. She holds a BS in
Psychology from University of Connecticut and an MBA from Pennsylvania
State University.

Yulii Bogatyrenko has over 20 years of experience in biopharmaceutical
and consumer businesses, with extensive experience in women’s health.
Most recently, he was Senior Vice President of Business Development at
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), where he developed global
and regional partnerships for the company’s anti-infective products and
led the company’s U.S. alliance with Allergan for Paratek’s dermatology
products. Previously, he was Vice President and General Manager at Teva
Pharmaceuticals Industries, Ltd. (NYSE: TEVA), where he led a specialty
women’s health business in Latin America, Asia, Middle East, India and
Africa. Prior to Teva, he had global responsibility for Bayer
Healthcare’s women’s health franchise. From 2006-2011, Mr. Bogatryrenko
was at the Pfizer Women’s Health Division, where he was responsible for
the cross-functional product teams in strategic planning and alliance
management. He holds a MA in Foreign Language and Literature from Moscow
Linguistics University and an MBA from New York University.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing products exclusively for women. With its
SYMBODA™ technology, TherapeuticsMD is developing advanced hormone
therapy pharmaceutical products to enable delivery of bio-identical
hormones through a variety of dosage forms and administration routes.
The company’s clinical development pipeline includes two phase 3
products. The company also manufactures and distributes branded and
generic prescription prenatal vitamins as well as over-the-counter
vitamins under the vitaMedMD® and BocaGreenMD®
brands. More information is available at the following websites:,,

Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include, but
are not limited to, statements relating to TherapeuticsMD’s objectives,
plans and strategies as well as statements, other than historical facts,
that address activities, events or developments that the company
intends, expects, projects, believes or anticipates will or may occur in
the future. These statements are often characterized by terminology such
as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,”
“plans,” “will,” “expects,” “estimates,” “projects,” “positioned,”
“strategy” and similar expressions and are based on assumptions and
assessments made in light of management’s experience and perception of
historical trends, current conditions, expected future developments and
other factors believed to be appropriate. Forward-looking statements in
this press release are made as of the date of this press release, and
the company undertakes no duty to update or revise any such statements,
whether as a result of new information, future events or otherwise.
Forward-looking statements are not guarantees of future performance and
are subject to risks and uncertainties, many of which are outside of the
company’s control. Important factors that could cause actual results,
developments and business decisions to differ materially from
forward-looking statements are described in the sections titled “Risk
Factors” in the company’s filings with the Securities and Exchange
Commission, including its most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and
include the following: the company’s ability to maintain or increase
sales of its products; the company’s ability to develop and
commercialize its hormone therapy drug candidates and obtain additional
financing necessary therefor; whether the FDA will approve the company’s
new drug application for its TX-004HR product candidate and whether any
such approval will occur by the PDUFA date; the length, cost and
uncertain results of the company’s clinical trials; the potential of
adverse side effects or other safety risks that could preclude the
approval of the company’s hormone therapy drug candidates; the company’s
reliance on third parties to conduct its clinical trials, research and
development and manufacturing; the availability of reimbursement from
government authorities and health insurance companies for the company’s
products; the impact of product liability lawsuits; the influence of
extensive and costly government regulation; the volatility of the
trading price of the company’s common stock and the concentration of
power in its stock ownership. PDF copies of the company’s historical
press releases and financial tables can be viewed and downloaded at its


TherapeuticsMD, Inc.
Investor Contact
DeLucia, 561-961-1900
Director, Investor Relations

Ami Knoefler, 650-739-9952